Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

<p>Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.</p>

Сохранить в:

Библиографические подробности
Главный автор:	Roberto Carmagnani Pestana (15294422) (author)
Другие авторы:	Justin T. Moyers (15047706) (author), Jason Roszik (15017091) (author), Shiraj Sen (15294425) (author), David S. Hong (15019257) (author), Aung Naing (15023555) (author), Cynthia E. Herzog (15012524) (author), Siqing Fu (15047712) (author), Sarina A. Piha-Paul (15294428) (author), Jordi Rodon (15047721) (author), Timothy A. Yap (15028749) (author), Daniel D. Karp (15294431) (author), Apostolia M. Tsimberidou (15294434) (author), Shubham Pant (15122815) (author), Maria A. Zarzour (15294437) (author), Ravin Ratan (15044195) (author), Vinod Ravi (15047730) (author), Robert S. Benjamin (15012521) (author), Alexander J. Lazar (14963562) (author), Wei-Lien Wang (15294440) (author), Najat Daw (15294443) (author), Jonathan B. Gill (15086581) (author), Douglas J. Harrison (15294446) (author), Valerae O. Lewis (15294449) (author), Christina L. Roland (15294452) (author), Shreyaskumar R. Patel (15062448) (author), J. Andrew Livingston (15294455) (author), Neeta Somaiah (14963553) (author), Joseph A. Ludwig (15016911) (author), Anthony P. Conley (15294458) (author), Nelson Hamerschlak (15294461) (author), Richard Gorlick (15019631) (author), Funda Meric-Bernstam (10258780) (author), Vivek Subbiah (8737068) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Drug Targets Precision Medicine Sarcomas
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

SPIRIT schedule of enrollment, interventions, and assessment.
по: Kim Christin Honselmann (21176936)
Опубликовано: (2025)

Participant timeline: Schedule of enrollment, interventions, and assessments.
по: Pierre Angelvy (22683450)
Опубликовано: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
по: Zoe Edwards (3823528)
Опубликовано: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
по: James S. Wilmott (15008931)
Опубликовано: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
по: James S. Wilmott (15008931)
Опубликовано: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
по: Iris van 't Erve (15054503)
Опубликовано: (2025)

Serum neuregulin -1 (NRG-1) is a potential biomarker for early diagnosis and prediction in refractory schizophrenia
по: Ming Shu (22683656)
Опубликовано: (2025)

Figure 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Figure 2 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Figure 3 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Figure 4 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Table 1 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma
по: Marianna Carrabotta (8193039)
Опубликовано: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
по: Sebastian Johannes Schober (14971891)
Опубликовано: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
по: Sebastian Johannes Schober (14971891)
Опубликовано: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
по: Sebastian Johannes Schober (14971891)
Опубликовано: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
по: Sebastian Johannes Schober (14971891)
Опубликовано: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
по: Sebastian Johannes Schober (14971891)
Опубликовано: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
по: Milana A. Bergamino (15038015)
Опубликовано: (2025)

Supplementary Table 1 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
по: David Olayinka Kamson (16617218)
Опубликовано: (2025)

Supplementary Table 2 from Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase–mutant Astrocytic and Oligodendroglial Tumors
по: David Olayinka Kamson (16617218)
Опубликовано: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
по: Nigel Bundred (15046233)
Опубликовано: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
по: Nigel Bundred (15046233)
Опубликовано: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
по: Nigel Bundred (15046233)
Опубликовано: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
по: Nigel Bundred (15046233)
Опубликовано: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
по: Nigel Bundred (15046233)
Опубликовано: (2025)

Table S1. Isometric handgrip force-matched participant demographics and LV morphology.
по: Corey Tomczak (22648301)
Опубликовано: (2025)

Data_Sheet_1_Benchmarking quantum annealing with maximum cardinality matching problems.PDF
по: Daniel Vert (18769933)
Опубликовано: (2025)

<b>Figure S1.</b><b> Cardiac MRI LV volume responses to EX and MMA in</b><b> </b><b>i</b><b>sometric handgrip force-matched-matched males and females</b>
по: Corey Tomczak (22648301)
Опубликовано: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
по: Benjamin K. Wilke (15055112)
Опубликовано: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
по: Benjamin K. Wilke (15055112)
Опубликовано: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
по: Tom Wei-Wu Chen (15053003)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mcldp0eb2nqakov77qq5mte080